VEGFA and renal cell carcinoma: Nonetheless, based on the positive results from this phase II study, the combination of lenvatinib (Lenvima®, Eisai Inc., Tokyo, Japan) and everolimus was recently approved in May 2016 by the FDA and in August 2016 by the EMA in advanced RCC for the treatment of patients pre-treated with one anti-VEGF target therapy.